Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products
Open Access
- 24 October 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 16 (1), 1-10
- https://doi.org/10.1186/s12967-018-1659-4
Abstract
Successful delivery of cell-based therapeutics into patients is compromised by their short shelf-life upon release from production facilities due to the living nature of the active component that rapidly loses viability, and therefore its properties. In this context, the use of appropriate additives may contribute to the stabilisation of the cellular component within specifications for a longer time until administration. In the present study, we evaluated the effect of different formulations on the stability of viability, identity, and potency of clinical grade multipotent mesenchymal stromal cells in suspension, both electrolyte solution and protein content were found to impact on their shelf-life. Particularly cryopreservation of cells in a Plasmalyte 148 supplemented with 2% (w/v) AlbIX (a yeast-derived recombinant albumin) and 10% (v/v) dimethyl sulfoxide, and final formulation post-thawing in Plasmalyte 148 supplemented with 2% (w/v) AlbIX enabling prolonged stability from 24 h up to 72 h in optimal conditions. Further investigation on the mechanisms of action involved revealed a delay of apoptosis progression into late stage when AlbIX was present. The use of optimal formulations for each cell type of interest is crucial to extend the shelf life of cell-based pharmaceuticals and contribute to solve logistical challenges. We demonstrated that the use of Plasmalyte 148 supplemented with 2% (w/v) AlbIX resulted in superior stability of multipotent mesenchymal stromal cells without affecting their identity and multipotency.Keywords
Funding Information
- Agència de Gestió d’Ajuts Universitaris i de Recerca (2017SGR898)
- Generalitat de Catalunya (2017SGR719)
- Instituto de Salud Carlos III (RD16/0011/0028)
This publication has 17 references indexed in Scilit:
- Derivation of Multipotent Mesenchymal Stromal Cells from Ovine Bone MarrowCurrent Protocols in Stem Cell Biology, 2018
- Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow–derived multipotent mesenchymal stromal cellsCytotherapy, 2016
- Final results of a phase I–II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regenerationThe Knee, 2016
- Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jellyCytotherapy, 2015
- White Paper on How to Go Forward with Cell-Based Advanced Therapies in EuropeTissue Engineering, Part A, 2014
- Study of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemiaEuropean Journal of Pharmaceutics and Biopharmaceutics, 2014
- Production of mesenchymal stromal/stem cells according to good manufacturing practices: a reviewStem Cell Research & Therapy, 2013
- Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical researchClinical and Experimental Medicine, 2012
- Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensingCytotherapy, 2012
- Challenges with advanced therapy medicinal products and how to meet themNature Reviews Drug Discovery, 2010